Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Smoldering (asymptomatic) multiple myeloma is an asymptomatic plasma-cell proliferative disorder associated with a high risk of progression to symptomatic multiple myeloma or amyloidosis. Prognostic factors for the progression and outcome of this disease are unclear. METHODS: We searched a computerized database and reviewed the medical records of all patients at Mayo Clinic who fulfilled the criteria of the International Myeloma Working Group for the diagnosis of smoldering multiple myeloma between 1970 and 1995. Bone marrow aspirate and biopsy specimens were studied, and patients were followed throughout the course of disease. RESULTS: During the 26-year period, 276 patients fulfilled the criteria for smoldering multiple myeloma. During 2131 cumulative person-years of follow-up, symptomatic multiple myeloma or amyloidosis developed in 163 persons (59%). The overall risk of progression was 10% per year for the first 5 years, approximately 3% per year for the next 5 years, and 1% per year for the last 10 years; the cumulative probability of progression was 73% at 15 years. At diagnosis, significant risk factors for progression included the serum level and type of monoclonal protein, the presence of urinary light chain, the extent and pattern of bone marrow involvement, and the reduction in uninvolved immunoglobulins. The proportion of plasma cells in the bone marrow and the serum monoclonal protein level were combined to create a risk-stratification model with three distinct prognostic groups. CONCLUSIONS: The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with SMM have a risk of progression of approximately 10% per year for the first 5 years, 3% per year for the next 5 years, and 1% per year thereafter.19”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [19]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationManual of Clinical Laboratory Immunology
Rose, N. R., Hamilton, R. G., & Detrick, B. (1992) · Cited by 1,250
Cited by
Items 201–300 of 932
Case 23-2013: A 54-Year-Old Woman with Abdominal Pain, Vomiting, and Confusion
Kalantar-Zadeh, K., Uppot, R. N., & Lewandrowski, K. B. (2013) · New England Journal of Medicine · doi:10.1056/nejmcpc1208154 · Cited by 49
Seckinger, A., Hillengaß, J., Emde, M., Beck, S., Kimmich, C. R., Dittrich, T., Hundemer, M., Jauch, A. S., Hegenbart, U., Raab, M., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01676 · Cited by 50
“(35) and the Mayo-model (36), number of affected organs, or the Mayo2004score (37)], cytogenetics and between defined groups were investigated by exact Wilcoxon rank-sum test (38).”
MethodHead and neck amyloidosis: clinicopathological features and immunohistochemical analysis of 14 cases
Gouvêa, A. F., Ribeiro, A. C. P., León, J. E., Carlos, R., de Almeida, O. P., & Lopes, M. A. (2011) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2011.01073.x · Cited by 48
Multiple myeloma – current issues and controversies
Kumar, S. K. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70006-2 · Cited by 53
Lozano, E., Mena, M.-P., Díaz, T., Martin-Antonio, B., León, S., Rodríguez-Lobato, L.-G., Oliver-Caldés, A., Cibeira, M. T., Bladé, J., Prat, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3673 · Cited by 47
“The risk of progression from asymptomatic SMM to symptomatic disease is related to the proportion of BMPCs and the serum monoclonal protein level at diagnosis, among other prognostic factors (4, 5).”
BackgroundMonoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All
Lomas, O., Mouhieddine, T. H., Tahri, S., & Ghobrial, I. M. (2020) · Cancers · doi:10.3390/cancers12061554 · Cited by 48
“Hypogammaglobulinemia is present in approximately 30% of patients with MGUS [4] and rises to 70% in smoldering multiple myeloma (SMM) [66].”
BackgroundInfluentialPathogenesis and treatment of multiple myeloma
Yang, P., Qu, Y., Wang, M., Chu, B., Chen, W., Zheng, Y., Niu, T., & Qian, Z. (2022) · MedComm · doi:10.1002/mco2.146 · Cited by 54
Kristinsson, S. Y., Minter, A. R., Korde, N., Tan, E., & Landgren, O. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.44 · Cited by 45
Urbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 45
“SMM may also have early active forms depending on genetic changes and require closer follow-up [15].”
BackgroundRole of imaging in multiple myeloma
Baffour, F. I., Glazebrook, K. N., Kumar, S. K., & Broski, S. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25846 · Cited by 49
“patients have an intermediary phase known as smoldering multiple myeloma (SMM) that is characterized by a significant increase in the plasma cell proliferation, but without end organ damage.(6) Progression”
BackgroundSingh, G. (2016) · Journal of Clinical Medicine Research · doi:10.14740/jocmr2802w · Cited by 54
“Kyle is credited with introducing the terms MGUS and SMM to the medical lexicon [12, 13].”
BackgroundGenome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 47
“Patients with SMM follow a declining logarithmic progression curve to symptomatic MM: 10% risk per year for the first 5 years following diagnosis, 3% risk per year for the following 5 years, and a subsequent 1% risk per year [1,8,13].”
BackgroundRuzafa, J. C., Merinopoulou, E., Baggaley, R. F., Leighton, P., Werther, W., Felici, D., & Cox, A. P. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3927 · Cited by 49
Mikhael, J. R., Bhutani, M., & Cole, C. E. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.08.030 · Cited by 47
Clinical characteristics and outcomes in biclonal gammopathies
Mullikin, T. C., Rajkumar, S. V., Dispenzieri, A. A., Buadi, F. K., Lacy, M. Q., Lin, Y., Dingli, D., Go, R. S., Hayman, S. R., Zeldenrust, S. R., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24319 · Cited by 42
“Currently, the progression of monoclonal disease is well established in that MGUS progresses to MM at 1% per year, whereas SMM is more aggressive, progressing to MM at an approximate rate of 10% per year during the initial 5 years [10,11].”
BackgroundSelf-citationC-src Enriched Serum Microvesicles Are Generated in Malignant Plasma Cell Dyscrasia
Noto, G. D., Paolini, L., Zendrini, A., Radeghieri, A., Caimi, L., & Ricotta, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070811 · Cited by 41
“The SMM asymptomatic plasma cell disorder carries a higher risk of progression (10% in the first 5 years) compared with MGUS [3].”
BackgroundDeep response in multiple myeloma: a critical review.
Fulciniti, M., Munshi, N. C., & Martinez-Lopez, J. (2015) · BioMed Research International · doi:10.1155/2015/832049 · Cited by 40
Laboratory assessment of multiple myeloma
Morrison, T., Booth, R. A., Hauff, K. D., Berardi, P., & Visram, A. (2019) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.12.001 · Cited by 47
Mateos, M.-V., Martínez-López, J., Rodriguez Otero, P., González-Calle, V., Gonzalez, M. S., Oriol, A., Gutiérrez, N. C., Ríos-Tamayo, R., Rosiñol, L., Alvarez Rivas, M. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02771 · Cited by 39
Staging and prognostication of multiple myeloma
Fonseca, R., Monge, J., & Dimopoulos, M. A. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882224 · Cited by 41
“Smoldering MM is an intermediate stage between MGUS and active MM [17].”
Self-citationPolyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders
Mittermayr, S., Le, G. N., Clarke, C., Millán‐Martín, S., Larkin, A., O’Gorman, P., & Bones, J. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00768 · Cited by 40
Mills, J. R., & Murray, D. L. (2017) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.020784 · Cited by 39
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
Jagannath, S., Laubach, J. P., Wong, E. Y.-M., Stockerl-Goldstein, K. E., Rosenbaum, C. A., Dhodapkar, M. V., Jou, Y., Lynch, M. J., Robbins, M. D. H., Shelat, S. G., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15384 · Cited by 39
Maatouk, I., He, S., Hummel, M., Hemmer, S., Hillengaß, M., Goldschmidt, H., Hartmann, M., Herzog, W., & Hillengaß, J. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0172-1 · Cited by 39
Chhabra, S., Jain, S., Wallace, C. H., Hong, F., & Liu, B. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0177-6 · Cited by 42
“It typically evolves from an asymptomatic pre-malignant stage called monoclonal gammopathy of undetermined significance (MGUS) [19–21], to an intermediate asymptomatic smoldering MM (SMM) [22], to eventually symptomatic MM.”
BackgroundThe effectiveness of exercise programmes in patients with multiple myeloma: A literature review
Gan, J. H., Sim, C. Y. L., & Santorelli, L. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.005 · Cited by 39
DNA Methylation of Tumor Suppressor Protein-Coding and Non-Coding Genes in Multiple Myeloma
Wong, K. Y., & Chim, C. S. (2015) · Epigenomics · doi:10.2217/epi.15.57 · Cited by 42
Misso, G., Zarone, M. R., Lombardi, A., Grimaldi, A., Cossu, A. M., Ferri, C., Russo, M., Vuoso, D. C., Luce, A., Kawasaki, H., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.023 · Cited by 39
“Another asymptomatic phase following MGUS is smoldering MM (SMM), characterized by a 10% average risk of progression to myeloma per year for the first 5 years from the occurrence of the disease, decreasing to 3% per year for the next 5 years and to 1%–2% per year for the next 10 years.(4) When pre-malignant disorders…”
InfluentialTakasu, M., Kaichi, Y., Tani, C., Date, S., Akiyama, Y., Kuroda, Y., Sakai, A., & Awai, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116842 · Cited by 38
“In previous reports [2,5], at the time of diagnosis, significant risk factors for progression have included the serum level and type of M protein, reductions in uninvolved immunoglobulins (Igs), and kappa/lambda ratio.”
BackgroundCurrent risk stratification and staging of multiple myeloma and related clonal plasma cell disorders
Zanwar, S., & Rajkumar, S. V. (2025) · Leukemia · doi:10.1038/s41375-025-02654-y · Cited by 44
“Unlike MGUS, the risk of progression of SMM to active MM is signi fi cantly higher at around 10% per year for the fi rst 5 years after diagnosis [44].”
Self-citationReiser, M., Borte, M., Huscher, D., Baumann, U., Pittrow, D., Sommer, C., Stangel, M., Faßhauer, M., Gold, R., & Hensel, M. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12900 · Cited by 40
Shall we treat smoldering multiple myeloma in the near future?
Landgren, O. (2017) · Hematology · doi:10.1182/asheducation-2017.1.194 · Cited by 35
“The reason they were labeled as having smoldering multiple myeloma is because they had 10% or more plasma cells in their bone marrow and/or they had M protein of at least 3 g per deciliter in the serum.(6) If there were better markers to designate these individuals to the MGUS category (instead of smoldering multiple…”
BackgroundMethodInfluentialImpact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
Goyal, G., Rajkumar, S. V., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dispenzieri, A. A., Hwa, Y. L., Fonder, A. L., Hobbs, M., Hayman, S. R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0419-7 · Cited by 39
Self-citationSanoja-Flores, L., Flores-Montero, J. A., Pérez‐Andrés, M., Puig, N., & Órfão, A. (2020) · Cancers · doi:10.3390/cancers12061499 · Cited by 40
“, smoldering MM (SMM) [9] or as symptomatic MM [10] with evidence of underlying organ dysfunction and/or predominant BM involvement.”
BackgroundGonsalves, W. I., Jang, J. S., Jessen, E., Hitosugi, T., Evans, L. A., Jevremović, D., Pettersson, X.-M., Bush, A. G., Gransee, J., Anderson, E. I., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-00235-4 · Cited by 40
Bustoros, M., Anand, S., Sklavenitis-Pistofidis, R., Redd, R., Boyle, E. M., Zhitomirsky, B., Dunford, A. J., Tai, Y.-T., Chavda, S. J., Boehner, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30694-w · Cited by 35
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 36
The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective
Caers, J., de Larrea, C. F., Leleu, X. P., Heusschen, R., Zojer, N., Decaux, O., Kastritis, E., Minnema, M. C., Jurczyszyn, A. J., Beguin, Y. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0303 · Cited by 39
Paquin, A. R., Kumar, S. K., Buadi, F. K., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Hwa, L., Fonder, A., Hobbs, M., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0163-7 · Cited by 35
Self-citationPursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
D’Agostino, M., Bertamini, L., Oliva, S., Boccadoro, M., & Gay, F. (2019) · Cancers · doi:10.3390/cancers11122015 · Cited by 41
“Mayo Clinic [47] 273 - M-protein <3 g/dL plus - BMPCs <10% 19 years - M-protein <3 g/dL plus - BMPCs ≥10% 8 years - M-protein ≥3 g/dL plus - BMPCs ≥10% 2 years”
Naina, H. V. K., Harris, S., Dispenzieri, A. A., Cosio, F. G., Habermann, T. M., Stegall, M. D., Dean, P. G., Prieto, M., Kyle, R. A., Rajkumar, S. V., et al. (2012) · American Journal of Nephrology · doi:10.1159/000337482 · Cited by 35
Self-citationRecent advances in the management of multiple myeloma.
Kumar, L., Verma, R. K., & Radhakrishnan, V. S. (2010) · PubMed · Cited by 36
Neurologic aspects of plasma cell disorders
Sobol, U., & Stiff, P. J. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-7020-4087-0.00073-5 · Cited by 37
Genomic landscape of multiple myeloma and its precursor conditions
Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32
Update on risk stratification and treatment of newly diagnosed multiple myeloma
Kapoor, P., & Rajkumar, S. V. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0947-z · Cited by 35
Self-citationCurrent Controversies in the Management of Myeloma Bone Disease
Silbermann, R. W., & Roodman, G. D. (2016) · Journal of Cellular Physiology · doi:10.1002/jcp.25351 · Cited by 33
Aljama, M. A., Sidiqi, M. H., Lakshman, A., Dispenzieri, A. A., Jevremović, D., Gertz, M. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Muchtar, E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024794 · Cited by 34
Self-citationCancer Immunoprevention: Current Status and Future Directions
Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-021-00604-x · Cited by 32
Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma
Pozzo, A. R., Yu, P. L. I., Lal, S., Asbaghi, Y., Sisdelli, L., Tammur, P., Tamm, A., Punab, M., Klewes, L., Louis, S. F., et al. (2021) · Cancers · doi:10.3390/cancers13081969 · Cited by 33
“MM was the only group that displayed lytic lesions, as well as a greatly elevated level of serum M-protein compared to MGUS and SMM patients [5].”
BackgroundResultBurgos, L., Tamariz‐Amador, L., Puig, N., Cedena, M., Guerrero, C., Jelínek, T., Johnson, S., Milani, P., Cordón, L., Pérez, J. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01916 · Cited by 34
“5% of them had high-risk disease according to the IMWG 20/2/20 and Mayo 2007 models.(1,30) These patients were included in clinical trials, which yielded a unique opportunity to compare the effect in TTP of early treatment versus observation.”
MethodRecommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma
Giralt, S., Jolles, S. R. A., Kerre, T. C. C., Lazarus, H. M., Mustafa, S. S., Papanicolaou, G. A., Ria, R., Vinh, D. C., & Wingard, J. R. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.05.008 · Cited by 36
“34 This rate of progression to MM is influenced by cytogenetic factors; patients with t(4;14) translocation, del(17p), and gain(1q) are at a high risk of progression from MGUS or SMM to MM. 44 , 45 Furthermore, a recent literature review highlighted that gut microbiota can modulate cancer immunity…”
BackgroundInfluentialBozorgpour, A., Azad, R., Showkatian, E., & Sulaiman, A. (2021) · COMPAY@MICCAI · doi:10.48550/arxiv.2105.06238 · Cited by 36
“Since myeloma cell can be differentiated from normal plasma cells based on histology and morphological features, it is a common method to diagnose multiple myeloma cancer through the aspirate slide images [15, 17, 18].”
MethodLandgren, O. (2010) · Hematology · doi:10.1182/asheducation-2010.1.295 · Cited by 40
Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance
Sigurbergsdóttir, A. Ý., Löve, Þ. J., & Kristinsson, S. Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876271 · Cited by 34
“In SMM, the annual risk of progression to malignancy is 10% in the first 5 years, 3% in the following 5 years and 1% after that (15).”
BackgroundFernando, R. C., Mazzotti, D. R., Azevedo, H., Sandes, A. F., Rizzatti, E. G., de Oliveira, M. B., Alves, V. L. F., Eugênio, A. I. P., de Carvalho, F., Dalboni, M. A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38314-8 · Cited by 28
Reconstructing the evolutionary history of multiple myeloma
Maura, F., Rustad, E. H., Boyle, E. M., & Morgan, G. J. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101145 · Cited by 34
“On average, the risk of progression from these precursors to MM ranges from 1% to 10% per year.(6, 7) The trajectory towards MM can be understood as an evolutionary process, where driver events accumulate over time conferring a competitive advantage to individual subclones, progressively shaping the genomic landscape…”
BackgroundZhou, X., Dierks, A., Kertels, O., Kircher, M., Schirbel, A., Samnick, S., Buck, A. K., Knorz, S., Böckle, D., Scheller, L., et al. (2020) · Cancers · doi:10.3390/cancers12082333 · Cited by 30
“, more than 70% of the patients with SMM progressed to MM after a follow-up period of 15 years [4].”
BackgroundLandgren, O. (2021) · Hematology · doi:10.1182/hematology.2021000303 · Cited by 32
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
Kaur, J., Valisekka, S. S., Hameed, M., Bandi, P. S., Varma, S., Onwughalu, C. J., Ibrahim, H., & Mongia, H. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.02.004 · Cited by 36
The Current Status and Future of Multiple Myeloma in the Clinic
Jagannath, S., Kyle, R. A., Palumbo, A. P., Siegel, D. S. D., Cunningham, S. A., & Berenson, J. R. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.003 · Cited by 33
Self-citationEfficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
Painuly, U., & Kumar, S. K. (2013) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7764 · Cited by 33
PET-CT in the UK: current status and future directions
Scarsbrook, A. F., & Barrington, S. F. (2016) · Clinical Radiology · doi:10.1016/j.crad.2016.02.023 · Cited by 32
Epidemiology of Hematologic Malignancies
Batista, J. L., Birmann, B. M., & Epstein, M. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-35153-7_29 · Cited by 35
Fiala, M. A., Dukeman, J., Tuchman, S. A., Keller, M., Vij, R., & Wildes, T. M. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00089 · Cited by 31
Current and future imaging modalities for multiple myeloma and its precursor states
Tan, E., Weiss, B. M., Mena, E., Korde, N., Choyke, P. L., & Landgren, O. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.573036 · Cited by 30
“The average risk of progression to multiple myeloma is approximately 1% per year for patients with MGUS and 10% per year for patients with SMM [46,47].”
BackgroundComparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience
Elboğa, U., Şahin, E., Çayırlı, Y. B., Okuyan, M., Aktaş, G., Şahin, H. H., Doğan, İ., Kuş, T., Akkurd, D. M., Çimen, U., et al. (2022) · Tomography · doi:10.3390/tomography8010024 · Cited by 30
Calorimetric Markers of Bence Jones and Nonsecretory Multiple Myeloma Serum Proteome
Todinova, S. J., Krumova, S., Radoeva, R., Gartcheva, L., & Taneva, S. G. (2014) · Analytical Chemistry · doi:10.1021/ac503677d · Cited by 29
Recent advances in multiple myeloma: a Korean perspective
Hong, J., & Lee, J. H. (2016) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.408 · Cited by 31
Rajkumar, S. V., Bergsagel, P. L., & Kumar, S. K. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.001 · Cited by 30
Self-citationMultiple Myeloma : Recent Progress in Diagnosis and Treatment
Chou, T. (2012) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.52.149 · Cited by 32
Oncolytic Viruses for Multiple Myeloma Therapy
Calton, C. M., Kelly, K. R., Anwer, F., Carew, J. S., & Nawrocki, S. T. (2018) · Cancers · doi:10.3390/cancers10060198 · Cited by 28
“An intermediary stage known as smoldering myeloma may occur during progression from MGUS to MM [4].”
BackgroundMaura, F., Landgren, O., & Morgan, G. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1395 · Cited by 26
“Intercepting these processes to prevent transition to cancer has clinical relevance inmultiple myeloma because 5% of the over 60-year-old population have a detectable monoclonal immunoglobulin that transforms tomultiplemyeloma at 1%–10%per annum a malignancy (5, 19).”
BackgroundHow I approach smoldering multiple myeloma
Vaxman, I., & Gertz, M. A. (2022) · Blood · doi:10.1182/blood.2021011670 · Cited by 32
Živković, S., Lacomis, D., & Lentzsch, S. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190903111922 · Cited by 28
“In patients with smoldering multiple myeloma, it remains unclear whether the occurrence of peripheral neuropathy signifies end-organ damage leading to reclassification as symptomatic myeloma requiring treatment [123].”
BackgroundPlasma Cell Labeling Index in the Evaluation of Smoldering (Asymptomatic) Multiple Myeloma
Madan, S., Kyle, R. A., & Greipp, P. R. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0653 · Cited by 28
Self-citationDisentangling clinical and biological trajectories of neurodegenerative diseases
Villain, N., & Planche, V. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01004-3 · Cited by 28
“For instance, an asymptomatic individual with abnormal but limited monoclonal serum protein and clonal plasma cell proliferation in the bone marrow will not be given a diagnosis of cancer, as they only have a 26% risk of progression to multiple myeloma 3 .”
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Vià, M. D., Ziccheddu, B., Maeda, A., Bagnoli, F., Perrone, G., & Bolli, N. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000502 · Cited by 30
“progression is not constant: it is 10%/year in the first 5 years, declining to 3% for the next 5 and to 1% after ten year from diagnosis.(80,81) This suggests that a heterogeneous group of patients may fall in the category of SMM: some with incipient”
BackgroundVisram, A., Rajkumar, S. V., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kourelis, T., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00569-2 · Cited by 27
“the first 5 years of SMM diagnosis, and then stabilizes at 3–5% annually thereafter [5, 7].”
BackgroundSelf-citationDetweiler‐Short, K., Hayman, S. R., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Kumar, S. K., Zeldenrust, S. R., Russell, S. J., Lust, J. A., Kyle, R. A., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21821 · Cited by 27
“[1] with the highest tumor burden had an average TTP of 27 months, and this group would more closely compare to our patients with IMM.”
BackgroundResultSelf-citationCooke, R. E., Gherardin, N. A., Harrison, S. J., Quach, H., Godfrey, D. I., Prince, M., Koldej, R. M., & Ritchie, D. S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0994-6 · Cited by 29
“MM bone marrow infiltrates can be variable and do not necessarily directly correlate with end-organ damage; however, a BM plasma cell infiltrate of >50 % is considered high risk [23].”
BackgroundMyeloma: Classification and Risk Assessment
Fonseca, R., & Monge, J. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.002 · Cited by 26
Self-citationSmoldering multiple myeloma: evolving diagnostic criteria and treatment strategies
Visram, A., Cook, J., & Warsame, R. M. (2021) · Hematology · doi:10.1182/hematology.2021000304 · Cited by 28
Factors That Regulate the Generation of Antibody-Secreting Plasma Cells
Yu, Y.-H., & Lin, K. (2016) · Advances in immunology · doi:10.1016/bs.ai.2016.03.001 · Cited by 29
Multiple Myeloma and Immunosecretory Disorders
Shaheen, S. P., Talwalkar, S. S., & Medeiros, L. J. (2008) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31817cfcd6 · Cited by 26
“Other findings include single or multiple sclerotic bone lesions, serosal effusions, papilledema, polycythemia, thrombocytosis, and lymphadenopathy, which often histologically resembles the plasma cell variant of Castleman disease.1,2,4,9,19,42–46 A recent retrospective study has accumulated data that proposed the use…”
BackgroundResultInfluentialRole of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma
Soliman, A. M., Teoh, S. L., Mahakkanukrauh, P., & Das, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207539 · Cited by 26
“Meanwhile, other patients are diagnosed with smoldering MM (SMM), an asymptomatic and more progressive pre-malignant stage, which could be detected through clinical examination and laboratory investigations [9].”
BackgroundManagement of Multiple Myeloma in Pregnancy: Strategies for a Rare Challenge
Kasenda, B., Rückert, A., Farthmann, J., Schilling, G., Schnerch, D., Prömpeler, H., Wäsch, R., & Engelhardt, M. M. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.009 · Cited by 25
Waxman, A. J., Kuehl, M. W., Balakumaran, A., Weiss, B. M., & Landgren, O. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.053 · Cited by 26
Recent advances in understanding multiple myeloma
Dhakal, B., Girnius, S. K., & Hari, P. (2016) · F1000Research · doi:10.12688/f1000research.8777.1 · Cited by 27
Management of older patients with multiple myeloma
Gay, F., & Palumbo, A. P. (2011) · Blood Reviews · doi:10.1016/j.blre.2010.10.003 · Cited by 27
“(8,9) (Table 1) Patients with symptomatic MM should be treated immediately; early intervention on asymptomatic patients showed no benefits, and observation alone is the standard.(10-12) Treatment choice should be based on both patient’s characteristics, in particular age, and scientific evidence.”
BackgroundMonoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis
Bouvard, B., Royer, M., Chappard, D., Audran, M., Hoppé, E., & Legrand, É. (2010) · Joint Bone Spine · doi:10.1016/j.jbspin.2009.12.002 · Cited by 26
Updates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review
Wu, F., Bernard, S., Fayad, L. M., Ilaslan, H., Messiou, C., Moulopoulos, L. A., & Mulligan, M. E. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.25878 · Cited by 25
Geraldes, C., Gonçalves, A. C., Cortesão, E., Pereira, M. I., Roque, A. I., Paiva, A. A., Ribeiro, L., Costa, N., & Sarmento‐Ribeiro, A. B. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.08.016 · Cited by 24
“Bone marrow plasma cell, median (range) (%) 5 (1-9) 12 (10-16) 30 (3-95)”
Familial myeloma and monoclonal gammopathy: A report of eight African American families
Jain, M. M., Ascensão, J. L., & Schechter, G. P. (2008) · American Journal of Hematology · doi:10.1002/ajh.21325 · Cited by 24
“By current criteria, this patient would be diagnosed as having progressed from MGUS to smoldering MM [17].”
BackgroundUtility of flow cytometry studies in the management of patients with multiple myeloma
Paiva, B., Merino, J., & Miguel, J. F. S. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000331 · Cited by 26
“In some patients, an intermediate asymptomatic but more advanced premalignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically, which progresses to multiple myeloma at a rate of approximately 10%/year over the first 5 years following diagnosis [3].”
BackgroundInfluentialGenetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism
Ni, L., Johnson, D. C., Weinhold, N., Kimber, S. T., Dobbins, S. E., Mitchell, J. S., Kinnersley, B., Sud, A., Law, P., Orlando, G., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.062 · Cited by 23
“Multiple myeloma (MM) is a malignancy of plasma cells primarily localized to the bone marrow (Kyle and Rajkumar, 2004; Kyle et al., 2007).”
BackgroundGiannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 30
González‐Calle, V., Dávila, J., Escalante, F., de Coca, A. G., Aguilera, C., López, R., Bárez, A., Alonso, J. M., Hernández, R. S., Hernández, J. M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.123 · Cited by 23
Dinarello, C. A. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.2.105 · Cited by 28
Raje, N. S., Hideshima, T., Yee, A. J., & Anderson, K. C. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm122 · Cited by 23
Luca, L. D., Laurenzana, I., Trino, S., Lamorte, D., Caivano, A., & Musto, P. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1583103 · Cited by 22
“gressively decreases after 5 years [2,4].”
Background
Metadata
- Authors
- Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2582-2590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1974983065
- Cited by
- 921
- References
- 25
- Citations by year
- 2026: 34 · 2025: 57 · 2024: 62 · 2023: 48 · 2022: 56 · 2021: 69 · 2020: 70 · 2019: 45 · 2018: 49 · 2017: 37 · 2016: 55 · 2015: 46 · 2014: 50 · 2013: 56 · 2012: 42
- FWCI
- 21.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 107 476, CA6 2242, R01CA107476, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Keywords
- smoldering multiple myeloma, asymptomatic multiple myeloma, amyloidosis, prognostic factors, risk stratification, clinical course
- MeSH terms
- Adult, Aged, Aged, 80 and over, Amyloidosis, Antibodies, Monoclonal, Biopsy, Bone Marrow Cells, Bone Marrow Examination, Female, Humans, Male, Middle Aged, Multiple Myeloma, Plasma Cells, Prognosis, Risk Factors, Cohort Studies, Disease Progression, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.